Agilent, 783975-906, AdvanceBio RP-mAb SB-C8, 4.6 x 150 mm, 3.5 µm

AdvanceBio RP-mAb SB-C8, 4.6 x 150 mm, 3.5 µm. A reversed-phase C8 HPLC column with superficially porous particles and a wide (450 Å) pore size designed for intact or subunit analysis of mAbs. StableBond technology ensures stability at low pH.

Specifications:
Brand: AdvanceBio RP mAb C8
Hardware: SS
Inner Diameter (ID): 4.6 mm
LC Platform: Stainless Steel
Length: 150 mm
Maximum Temperature: 90 °C
Part Number Application Domain: Biopharma
Part Number Application: Intact & Subunit AnalysisMonoclonal Antibodies (mABs)Proteins
Particle Size: 3.5 µm
Particle Type: Superficially Porous
Phase: SB-C8
Pore Size: 450 Å
Pressure Rating: 600 bar
Separation Mode: Reversed Phase
Shipping Solvent: Acetonitrile/Water
Technique: LCLC & LC/MS
UNSPSC Code: 41115711
pH Range: 1-8

**********The following product description is generated by AI and is for reference only. If you have any questions, please contact customer service.**********
Engineered for high performance in reversed-phase chromatography, this column incorporates advanced silica-based C8 bonded phase technology, specifically optimized for the analysis of monoclonal antibodies, antibody fragments, and related biotherapeutics. With a particle size of 3.5 micrometers and dimensions of 4.6 by 150 millimeters, the column delivers robust retention and reproducible peak shape for hydrophobic or moderately polar protein samples. It supports high resolution and superior throughput in critical quality attribute assessment and impurity profiling, making it ideal for development and quality control environments in pharmaceutical or biopharmaceutical laboratories.

Designed for compatibility with leading HPLC and UHPLC systems, the column enables rapid method development, batch comparison, and detailed characterization of intact proteins and subunit mapping. It can be seamlessly integrated into workflows alongside other AdvanceBio columns to offer a comprehensive portfolio for biotherapeutic analysis. Its stable performance at high temperatures and a broad range of mobile phases ensures reliable results, even with complex sample matrices. This solution is an essential tool for researchers engaged in method validation, biosimilarity studies, or routine lot release testing, supporting confident decision-making in biotherapeutic research and production.